Skip to content
mielomamultiplo.com · Multiple Myeloma
Emergency 112  · SNS 24 808 24 24 24
The Multiple Myeloma symbol — find out what it means

Multiple Myeloma There is hope. There is a way forward.

information · support · hope

It is always better to be an informed patient.

News, testimonies, a space to share ideas and links that help patients and carers understand the disease better and know where to find help.

Automatic translation by MielomaAI. The original text is in Portuguese. Some parts may still appear in Portuguese while they are being translated. Português
Summary · Access to medicines, prices and funding

Recent developments regarding multiple myeloma highlight advances in access to medications and funding. [Brazil] Tocantins has incorporated daratumumab into treatment, while [Portugal] the SNS has begun to fund new therapeutic combinations. The approval of medications such as Iberdoma [USA] and the expansion of the Melflufen monograph [USA] are also important milestones.

Made by MielomaAI On November 17, 2026, at 10:32, from recent news. May contain errors. View news →

CAR-T in myeloma: Portugal and other countries

How much a CAR-T treatment costs and how much the patient pays. Prices negotiated by health services are almost always confidential; here are the public figures.

Portugal (estimate)350.000 €Spain (SNS, Carvykti)353.000 €Germany (foreign patient)470.000 €

In euros, per treatment. The USA and Brazil are in the table below, also in euros.

CountryPublic price per treatmentWhat the patient paysSource
PortugalConfidential. Government estimate in 2019: about €350,000. Median total cost at IPO Porto: €355,165.0 € in the SNS. Carvykti funded since 26 May 2025.Source: Infarmed ↗
Spain€353,000 excluding VAT (deduced from Madrid's public contracts).€0 in the public system. Carvykti included in the Spanish SNS in April 2025, from the 2nd line.Source: Ministerio de Sanidad ↗
GermanyA public hospital asked a foreign patient for about €470,000 (2019 report, CAR-T in general).For residents, paid by health insurance.Source: Notícias ao Minuto ↗
United KingdomNo public price for myeloma CAR-T. Carvykti is still being assessed by NICE; Abecma was not assessed because the company did not submit data.No routine access on the NHS (November 2026).Source: NICE ↗
USA502.452 € (Carvykti, 2025) · 478.024 € (Abecma, 2025)Depends on insurance; there may be high co-payments.Source: HMPI 2026 ↗
BrazilMore than 485.846 € (commercial CAR-T).Outside the SUS; access mainly through the courts and health plans.Source: Futuro da Saúde ↗

Amounts converted to euros: €1 = 1.1052 dollars and 6.1748 reais (European Central Bank reference rates of 13/11 and 09/11/2026) and 0.8336 pounds (market rate of 05/11/2026). The original amounts are in the sources. List prices do not include confidential discounts.

Latest news on access, pricing and funding

All news → · Summaries created by MielomaAI; expand the article to read the original.